Mesoblast Limited (AU:MSB) has released an update.
Mesoblast Limited has announced the settlement of a consolidated shareholder class action from 2022, with no admission of liability and the company’s insurers covering all costs, ensuring no financial impact on Mesoblast’s cashflow or results. The company focuses on developing cellular medicines for severe inflammatory conditions and has a strong global intellectual property portfolio, with commercial partnerships for Phase 3 assets and products commercialized in Japan and Europe.
For further insights into AU:MSB stock, check out TipRanks’ Stock Analysis page.
